MOS Prebiotic Potential in Older Adults

Not Applicable

Active, not recruiting

• Conditions: Healthy
• Interventions: Dietary Supplement: Mannooligosaccharides yeast extract

• Registration Number: NCT05939336
• Lead Sponsor: University of Florida

Brief Summary

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Detailed Description

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Study Timeline

• Study First Submitted: 2023-07-03
• Study First Submitted QC: 2023-07-03
• Study First Posted: 2023-07-11
• Study Start: 2023-08-01
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-23
• Last Update Posted: 2025-01-24
• Primary Completion: 2025-09-30
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Adults 50-99 years of age.
• Able to provide written informed consent in English.
• Willingness to complete all study procedures
• Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion Criteria

• Yeast allergy.
• Self-reported kidney disease.
• Elite athletes or long-distance runners.
• Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
• Current use of laxatives or antidiarrheal medications.
• Use of other investigational products within 3 months of the screening visit.
• Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
• Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
• Current cancer treatment
• Currently pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Mannooligosaccharides	Mannooligosaccharides yeast extract	Mannooligosaccharides yeast extract

Primary Outcome Measures

Name	Time	Method
Mean daily rating of gastrointestinal symptoms	14 days	Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)

Trial Locations

Locations (1)

Food Science and Human Nutrition Department, University of Florida; 🇺🇸 Gainesville, Florida, United States